Lost Money on Myriad Genetics, Inc. (MYGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. (MYGN) for potential federal securities law violations. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test from January 2025.
November 05, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities law violations after UnitedHealth Group announced it would stop covering the GeneSight test.
The investigation by Levi & Korsinsky into Myriad Genetics for potential securities law violations is significant, especially following UnitedHealth's decision to cease coverage of GeneSight. This could negatively impact Myriad's stock price due to potential legal repercussions and loss of revenue from GeneSight.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100